Forest Labs - High dose of schizophrenia drug doesn't meet goal

Oct 15 (Reuters) - Forest Laboratories Inc (FRX.N) said high doses of its experimental antipsychotic drug did not show statistically significant improvement in a mid-stage trial for the treatment of schizophrenia.

However, low doses of the drug, RGH-188, showed a nominally statistically significant effect, Forest and Hungary's Gedeon Richter Plc GDRB.BU said in a statement.

The companies said they plan to continue developing the drug as a treatment for schizophrenia. (Reporting by Esha Dey in Bangalore)